0AAJ.LPolyPeptide Group AG

Über

Operating globally, PolyPeptide Group AG functions as a prominent contract development and manufacturing organization (CDMO). The company specializes in producing both proprietary and generic GMP-certified peptides, which are supplied to pharmaceutical and biotechnology firms. These crucial components are integrated into approved pharmaceutical products, drugs in various stages of clinical development, and generic medications. PolyPeptide Group also handles the manufacturing of bespoke research-grade peptides and is engaged in the development of neoantigen peptides designed to advance personalized cancer therapies. Its services further encompass the production of peptides for commercially available peptide therapeutics, as well as the creation of peptide-based generics for both human and animal health sectors, alongside peptides for the cosmetics industry. Additionally, the company offers vital regulatory affairs assistance. Established in 1952, PolyPeptide Group AG maintains its corporate headquarters in Zug, Switzerland, and operates as a subsidiary of Draupnir Holding B.V.

www.polypeptide.com

Kennzahlen

Marktkapitalisierung

1.57B

EPS

-0.64

Dividendenrendite

0.00%

Beta

1.03

KBV

2.70

EK-Rendite

-6.3%

Sektor

Healthcare

Branche

Drug Manufacturers - Specialty & Generic

CEO

Juan Jose Gonzalez

Mitarbeiter

1.362

IPO-Datum

2021-11-12

Land

CH